Does the media favor ABBV or IRWD?

In the previous week, AbbVie had 85 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 96 mentions for AbbVie and 11 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 0.79 beat Ironwood Pharmaceuticals' score of 0.23 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 48 Very Positive mention(s) 13 Positive mention(s) 18 Neutral mention(s) 9 Negative mention(s) 2 Very Negative mention(s) Positive Ironwood Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BCRX or IRWD?

In the previous week, Ironwood Pharmaceuticals had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 11 mentions for Ironwood Pharmaceuticals and 8 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.33 beat Ironwood Pharmaceuticals' score of 0.23 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ironwood Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ZBIO or IRWD?

In the previous week, Ironwood Pharmaceuticals had 7 more articles in the media than Zenas BioPharma. MarketBeat recorded 11 mentions for Ironwood Pharmaceuticals and 4 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.64 beat Ironwood Pharmaceuticals' score of 0.23 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ironwood Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor INVA or IRWD?

In the previous week, Ironwood Pharmaceuticals had 2 more articles in the media than Innoviva. MarketBeat recorded 11 mentions for Ironwood Pharmaceuticals and 9 mentions for Innoviva. Innoviva's average media sentiment score of 0.96 beat Ironwood Pharmaceuticals' score of 0.23 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Ironwood Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NVAX or IRWD?

In the previous week, Ironwood Pharmaceuticals had 2 more articles in the media than Novavax. MarketBeat recorded 11 mentions for Ironwood Pharmaceuticals and 9 mentions for Novavax. Ironwood Pharmaceuticals' average media sentiment score of 0.23 beat Novavax's score of -0.01 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Ironwood Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Ironwood Pharmaceuticals (IRWD) Competitors

$4.31 -0.11 (-2.49%)

Closing price 04:00 PM Eastern

Extended Trading

$4.32 +0.02 (+0.35%)

As of 06:11 PM Eastern

Compare

IRWD vs. ABBV, BCRX, ZBIO, INVA, and NVAX

Should you buy Ironwood Pharmaceuticals stock or one of its competitors? MarketBeat compares Ironwood Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ironwood Pharmaceuticals include AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), Innoviva (INVA), and Novavax (NVAX).

How does Ironwood Pharmaceuticals compare to AbbVie?

AbbVie (NYSE:ABBV) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

70.2% of AbbVie shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

AbbVie presently has a consensus price target of $272.76, suggesting a potential upside of 11.86%. Ironwood Pharmaceuticals has a consensus price target of $6.23, suggesting a potential upside of 44.62%. Given Ironwood Pharmaceuticals' higher probable upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	7.04	$4.23B	$3.54	68.88
Ironwood Pharmaceuticals	$296.15M	2.37	$24.02M	$0.60	7.18

In the previous week, AbbVie had 85 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 96 mentions for AbbVie and 11 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 0.79 beat Ironwood Pharmaceuticals' score of 0.23 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	48 Very Positive mention(s)	13 Positive mention(s)	18 Neutral mention(s)	9 Negative mention(s)	2 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ironwood Pharmaceuticals has a net margin of 28.26% compared to AbbVie's net margin of 9.80%. Ironwood Pharmaceuticals' return on equity of -39.65% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-466.39%	14.35%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

AbbVie has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Summary

AbbVie beats Ironwood Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Ironwood Pharmaceuticals has a net margin of 28.26% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Ironwood Pharmaceuticals' return on equity of -39.65% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

BioCryst Pharmaceuticals has higher revenue and earnings than Ironwood Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.62	$263.86M	-$1.78	N/A
Ironwood Pharmaceuticals	$296.15M	2.37	$24.02M	$0.60	7.18

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Ironwood Pharmaceuticals had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 11 mentions for Ironwood Pharmaceuticals and 8 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.33 beat Ironwood Pharmaceuticals' score of 0.23 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals currently has a consensus price target of $20.80, indicating a potential upside of 130.60%. Ironwood Pharmaceuticals has a consensus price target of $6.23, indicating a potential upside of 44.62%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

BioCryst Pharmaceuticals has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Summary

BioCryst Pharmaceuticals beats Ironwood Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, Ironwood Pharmaceuticals had 7 more articles in the media than Zenas BioPharma. MarketBeat recorded 11 mentions for Ironwood Pharmaceuticals and 4 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.64 beat Ironwood Pharmaceuticals' score of 0.23 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ironwood Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	198.35	-$377.74M	-$8.47	N/A
Ironwood Pharmaceuticals	$296.15M	2.37	$24.02M	$0.60	7.18

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Zenas BioPharma's net margin of 0.00%. Ironwood Pharmaceuticals' return on equity of -39.65% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

Zenas BioPharma has a beta of -1.03, suggesting that its share price is 203% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Zenas BioPharma currently has a consensus target price of $44.29, indicating a potential upside of 40.95%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 44.62%. Given Ironwood Pharmaceuticals' higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Summary

Ironwood Pharmaceuticals beats Zenas BioPharma on 11 of the 15 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Innoviva?

Innoviva (NASDAQ:INVA) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Innoviva has higher revenue and earnings than Ironwood Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.74	$271.17M	$6.01	3.47
Ironwood Pharmaceuticals	$296.15M	2.37	$24.02M	$0.60	7.18

Innoviva has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Innoviva presently has a consensus target price of $36.20, suggesting a potential upside of 73.54%. Ironwood Pharmaceuticals has a consensus target price of $6.23, suggesting a potential upside of 44.62%. Given Innoviva's higher probable upside, equities research analysts clearly believe Innoviva is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Innoviva has a net margin of 119.89% compared to Ironwood Pharmaceuticals' net margin of 28.26%. Innoviva's return on equity of 33.33% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

In the previous week, Ironwood Pharmaceuticals had 2 more articles in the media than Innoviva. MarketBeat recorded 11 mentions for Ironwood Pharmaceuticals and 9 mentions for Innoviva. Innoviva's average media sentiment score of 0.96 beat Ironwood Pharmaceuticals' score of 0.23 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Innoviva shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Innoviva beats Ironwood Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Novavax?

Novavax (NASDAQ:NVAX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Novavax has a beta of 2.47, suggesting that its share price is 147% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

53.0% of Novavax shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

Novavax has higher revenue and earnings than Ironwood Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.12	$440.30M	-$0.58	N/A
Ironwood Pharmaceuticals	$296.15M	2.37	$24.02M	$0.60	7.18

In the previous week, Ironwood Pharmaceuticals had 2 more articles in the media than Novavax. MarketBeat recorded 11 mentions for Ironwood Pharmaceuticals and 9 mentions for Novavax. Ironwood Pharmaceuticals' average media sentiment score of 0.23 beat Novavax's score of -0.01 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ironwood Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novavax currently has a consensus target price of $13.00, indicating a potential upside of 69.71%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 44.62%. Given Novavax's higher probable upside, equities research analysts plainly believe Novavax is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Summary

Ironwood Pharmaceuticals beats Novavax on 9 of the 16 factors compared between the two stocks.

Get Ironwood Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRWD vs. The Competition

Export

Metric	Ironwood Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$702.79M	$3.56B	$6.80B	$13.02B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	7.18	7.36	279.72	25.54
Price / Sales	2.37	1,274.64	648.69	115.96
Price / Cash	16.43	44.80	28.64	34.82
Price / Book	-2.68	17.08	11.12	6.36
Net Income	$24.02M	-$12.52M	$3.48B	$347.58M
7 Day Performance	13.42%	2.52%	2.58%	3.16%
1 Month Performance	-0.46%	-5.36%	-2.79%	-2.06%
1 Year Performance	474.28%	51.37%	64.28%	21.19%

Ironwood Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRWD Ironwood Pharmaceuticals	2.7911 of 5 stars	$4.31 -2.5%	$6.23 +44.6%	+473.0%	$702.79M	$296.15M	7.18	220	Upcoming Earnings Gap Up
ABBV AbbVie	4.7405 of 5 stars	$262.62 +2.2%	$268.10 +2.1%	+25.3%	$464.86B	$61.16B	129.61	57,000	Trending News Earnings Report Analyst Forecast
BCRX BioCryst Pharmaceuticals	3.8193 of 5 stars	$9.69 +1.2%	$20.80 +114.6%	+10.8%	$2.47B	$874.84M	N/A	530	Positive News Upcoming Earnings
ZBIO Zenas BioPharma	3.4892 of 5 stars	$32.49 -1.0%	$44.29 +36.3%	+102.0%	$2.03B	$10M	N/A	N/A	News Coverage Upcoming Earnings
INVA Innoviva	3.2134 of 5 stars	$21.65 +1.7%	$36.20 +67.2%	+11.5%	$1.58B	$420.69M	3.56	100	Upcoming Earnings Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRWD) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, BCRX, ZBIO, INVA, and NVAX

How does Ironwood Pharmaceuticals compare to AbbVie?

Summary

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Ironwood Pharmaceuticals compare to Zenas BioPharma?

Summary

How does Ironwood Pharmaceuticals compare to Innoviva?

Summary

How does Ironwood Pharmaceuticals compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, BCRX, ZBIO, INVA, and NVAX

How does Ironwood Pharmaceuticals compare to AbbVie?

Do institutionals and insiders hold more shares of ABBV or IRWD?

Do analysts recommend ABBV or IRWD?

Which has preferable earnings & valuation, ABBV or IRWD?

Does the media favor ABBV or IRWD?

Is ABBV or IRWD more profitable?

Which has more volatility & risk, ABBV or IRWD?

Summary

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

Is BCRX or IRWD more profitable?

Which has higher earnings and valuation, BCRX or IRWD?

Do institutionals & insiders have more ownership in BCRX or IRWD?

Does the media refer more to BCRX or IRWD?

Do analysts rate BCRX or IRWD?

Which has more volatility & risk, BCRX or IRWD?

Summary

How does Ironwood Pharmaceuticals compare to Zenas BioPharma?

Does the media prefer ZBIO or IRWD?

Which has better earnings and valuation, ZBIO or IRWD?

Is ZBIO or IRWD more profitable?

Which has more volatility and risk, ZBIO or IRWD?

Do analysts rate ZBIO or IRWD?

Summary

How does Ironwood Pharmaceuticals compare to Innoviva?

Which has preferable earnings and valuation, INVA or IRWD?

Which has more volatility & risk, INVA or IRWD?

Do analysts recommend INVA or IRWD?

Is INVA or IRWD more profitable?

Does the media favor INVA or IRWD?

Do institutionals & insiders hold more shares of INVA or IRWD?

Summary

How does Ironwood Pharmaceuticals compare to Novavax?

Which has more risk and volatility, NVAX or IRWD?

Do insiders & institutionals have more ownership in NVAX or IRWD?

Is NVAX or IRWD more profitable?

Which has preferable valuation & earnings, NVAX or IRWD?

Does the media favor NVAX or IRWD?

Do analysts recommend NVAX or IRWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools